Drug facts
MoleculePomalidomide (Pomalyst)
Generics already compete: 10 makers on the market. 39 A-rated products from 10 makers substitute at the counter.
Pomalyst was first approved by the FDA on 02/08/2013 under NDA 204026; the application holder is Bristol Myers Squibb Co.
Holder Bristol Myers Squibb CoApplication NDA 204026Approved 02/08/2013
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
1,877days until the latest patent expires
ExclusivityPatent onlyOpen to generics
Today
Approved02/08/2013
Exclusivity ends11/14/2027
Last patent12/21/2031
2014201720202023202620292032
- Latest patent
- 12/21/2031Pomalyst Orange Book
- Exclusivity
- 11/14/2027Pomalyst Orange Book
02Competition
- Generics
- 10 generic makers Orange Book
- First generic approved
- 10/30/2020 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Pomalidomide profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
04Product
- Application holder
- Bristol Myers Squibb Co Orange Book
- Application
- NDA 204026 Orange Book
- First approved
- 02/08/2013 Orange Book
- Dosage forms
- capsule
- Routes
- oral
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.